InvestorsHub Logo

JediMozart

09/27/21 1:41 PM

#10743 RE: Dapper10 #10741

Here’s the article pasted in it’s entirety below - I’m not sure why the link didn’t work…

It’s amazing how effective escozine Is with not only covid but in conjunction with the vaccine as well … add in all the AELIA products and the company’s

Business
Quanta, Inc.: Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19
July 8, 2021, 8:30 AM EDT
BURBANK, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife
Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D,
manufacturing, and consumer product distribution, which is a majority owned
subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today new clinical
observations made on its lead drug candidate Escozine®.

Physicians observed that patients who originally had strong adverse reactions
to COVID-19 vaccines and who were given Escozine®, experienced significantly
lessened side effects. Typical vaccine side effects are similar to symptoms of
the actual COVID-19 virus, including body cough, aches, fatigue and fever,
among others.

These observations have led the Company to move forward with pursuing an
additional pilot study on the drug, looking to prove its effectiveness in
decreasing side effects of vaccinations for COVID-19. Management plans to meet
with the Ministry of Health and the office of the President of the DR to
present the observations and seek further guidance on next steps for approval
as a complimentary product for vaccine recipients.

“It only makes sense that Escozine® would be effective in mitigating side
effects of COVID-19 vaccines as it has been proven to be effective in treating
or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO
Dr. Arthur Mikaelian. “Specifically in the DR, and in many places around the
world, vaccine hesitancy is becoming more common for a multitude of reasons,
including the side effects associated with them. While the idea of pursuing
Escozine® as a complementary product to COVID-19 vaccines was not originally
included in our study parameters, we plan to quickly initiate a pilot study in
order to prove its potential effectiveness as such. If we are able to do so,
Escozine® could have global applications as a complementary medicine,
decreasing the severity of side effects of COVID-19 vaccines, and hopefully,
decreasing vaccine hesitancy in patients with a high side effect risk rate.”

The Company is currently pursuing approval of Escozine® as both a palliative
and therapeutic treatment for the virus in the US and the DR, with positive
data from preclinical studies suggesting its effectiveness. Given that
Escozine® has received product registration as a natural alternative medicine
in Dominican and been a part of these clinical studies, physicians at the
clinic provided doses to certain vaccine recipients and observed this
reduction in side effects.

Escozine®, which is comprised of scorpion peptides that have been polarized by
the Company’s proprietary process, is Medolife’s lead drug candidate. The
Company recently announced that it has received a detailed response from the
US Food and Drug Administration (FDA) on its Pre-Investigational New Drug
(Pre-IND) submission on Escozine® as both a potential palliative and
therapeutic drug for the COVID-19 virus. In the response, the FDA acknowledged
the Company’s clinical trial that took place in the DR as a proof-of-concept
study and provided detailed guidelines for next steps in its approval process.
The Company is in the process of outlining an additional DNA toxicology study
as well as a formal clinical Pharmacokinetic (PK) study that it hopes to
launch in short order.

About Medolife Rx

Medolife Rx, Inc. is a global biotechnology company with operations in
clinical research, manufacturing, and consumer products. Medolife Rx was
created through the merger of Medolife, a private company founded by Dr.
Arthur Mikaelian who pioneered the unlaying polarization technology that makes
the Company’s portfolio of pharmaceutical and nutraceutical products so
effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio
company. The Company’s lead clinical development programs include Escozine®, a
proprietary formulation consisting of small molecule peptides derived from
Rhopalurus princeps scorpions, which is amplified by the Company’s
polarization technology and is being researched as a treatment of various
indications, including COVID-19 and cancer. The Company has completed
preclinical safety and efficacy research on Escozine® and is pursuing product
registration and drug approval in various countries, including the United
States and throughout Latin America.

Through its subsidiary QuantRx, Medolife manufactures and distributes consumer
wellness products in high-impact consumer areas such as pain relief, beauty,
and general wellness. QuantRx products are designed using Dr. Mikaelian’s
polarization technology, which applies advances in quantum biology to increase
the potency of active ingredients. Ultimately, Quanta's mission is to deliver
better, more effective ingredients to elevate product efficacy, reduce waste,
and facilitate healthier, more sustainable consumption.

Beyond its own clinical and consumer applications, the polarization technology
used by Medolife and its subsidiaries has many potential applications. From
potentiating bio-ingredients, to producing more-effective carbon-trapping
plants, to transformative anti-aging solutions, Medolife has the opportunity
to upend how commercial and pharmaceutical products are made and increase
their benefits, while decreasing their chemical concentration.

Forward-Looking Statements

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act
of 1995: This release contains statements that are forward-looking in nature
which express the beliefs and expectations of management including statements
regarding the Company's expected results of operations or liquidity;
statements concerning projections, predictions, expectations, estimates or
forecasts as to our business, financial and operational results and future
economic performance; and statements of management's goals and objectives and
other similar expressions concerning matters that are not historical facts. In
some cases, you can identify forward-looking statements by terminology such as
"anticipate," "estimate," "plan," "project," "continuing," "ongoing,"
"expect," "we believe," "we intend," "may," "will," "should," "could," and
similar expressions. Such statements are based on current plans, estimates and
expectations and involve a number of known and unknown risks, uncertainties
and other factors that could cause the Company's future results, performance
or achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. These
factors and additional information are discussed in the Company's filings with
the Securities and Exchange Commission and statements in this release should
be evaluated in light of these important factors. Although we believe that
these statements are based upon reasonable assumptions, we cannot guarantee
future results. Forward-looking statements speak only as of the date on which
they are made, and the Company undertakes no obligation to update publicly or
revise any forward-looking statement, whether as a result of new information,
future developments or otherwise.

Contacts:
medolife@cmwmedia.com

https://www.bloomberg.com/press-releases/2021-07-08/quanta-inc-medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19